Beigene Ltd (ADR) - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BGNE Nasdaq 2834 http://www.beigene.cn/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Beigene Ltd (ADR)

BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio - May 26th, 2022 9:00 pm
BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland - May 17th, 2022 5:00 am
BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress - May 12th, 2022 2:00 pm
Biotech Stocks Hammered On Roche's Unexpected Failure In Lung Cancer - May 11th, 2022 8:09 pm
Despite currently being unprofitable, BeiGene (NASDAQ:BGNE) has delivered a 304% return to shareholders over 5 years - May 9th, 2022 7:15 pm
Amarin (AMRN) Q1 Earnings & Sales Hurt by Vascepa Generics - May 5th, 2022 3:30 pm
BeiGene Reports First Quarter 2022 Financial Results - May 5th, 2022 11:00 am
Why Earnings Season Could Be Great for BeiGene (BGNE) - May 4th, 2022 5:48 pm
5 Large-Cap Stocks to Buy Ahead of Q1 Earnings This Week - May 4th, 2022 11:02 am
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL) - May 4th, 2022 9:53 am
BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey - Apr 29th, 2022 11:00 am
BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Waldenström’s Macroglobulinemia - Apr 28th, 2022 11:00 am
BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting - Apr 27th, 2022 2:00 pm
Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial - Apr 27th, 2022 1:45 pm
Global Phase 3 Trial of BeiGene’s PD-1 Inhibitor, Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma - Apr 27th, 2022 10:00 am
BeiGene Introduces Global Environmental, Social, and Governance Strategy - Apr 26th, 2022 11:00 am
Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene - Apr 25th, 2022 8:09 pm
COVID-19 wave in China prompts sell-off in global markets - Apr 25th, 2022 1:28 pm
BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Cancer Patients and Communities in New Jersey - Apr 21st, 2022 11:00 am
BeiGene Shares Updated Data From Tislelizumab Combo Trial In Head & Neck Cancer - Apr 19th, 2022 3:33 pm